Noticias de Eulerpool ALX Oncology Holdings

ALX Oncology Holdings Noticias de Acciones

ALX Oncology Holdings es observado por muchos periodistas e inversores en todo el mundo. Aquí recopilamos las noticias más recientes de ALX Oncology Holdings.

• 30 de mayo ·

  Yahoo
  ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference
• 20 de mayo ·

  Yahoo
  ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event
• 13 de mayo ·

  Yahoo
  ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
• 8 de mayo ·

  Yahoo
  ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
• 2 de mayo ·

  Yahoo
  ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025
• 28 de abril ·

  Yahoo
  ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials
• 25 de abril ·

  Yahoo
  ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
• 25 de abril ·

  Yahoo
  ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints
• 7 de abril ·

  Yahoo
  ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
• 27 de febrero ·

  Yahoo
  ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025